Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

68 trials

NCT07056595
Recruiting
Finerenone in Patients With IgA-nephropathy: Prospective Interventional Trial
Not applicable · Russia · 1 site
Registry update: 9 Jul 2025
NCT06935357
Recruiting
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
Phase 3 · Argentina, Australia, Belgium, Bulgaria, Brazil, Canada, China, Colombia, Czechia, Germany, Spain, France, United Kingdom, Greece, Croatia, India, Italy, Japan, South Korea, Malaysia, New Zealand, Philippines, Poland, Puerto Rico, Portugal, Taiwan, United States · 264 sites
Registry update: 14 Oct 2026
NCT06952426
Recruiting
A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US
Not applicable · United States · 1 site
Registry update: 17 Jun 2025
NCT06797518
Recruiting
Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN
Phase 2 · Argentina, Israel, Malaysia, Saudi Arabia, United States · 17 sites
Registry update: 29 Jul 2026
NCT06676384
Recruiting
Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy?
Phase 4 · India · 12 sites
Registry update: 14 Jul 2025
NCT06819826
Recruiting
A Study of SC0062 Capsule for the Treatment of IgA Nephropathy with Proteinuria
Phase 3 · China · 1 site
Registry update: 17 Feb 2025
NCT06792799
Recruiting
Anti-CD19/BCMA CAR-NK Cells in Patients With B Cell Mediated Autoimmune Disease
Early phase 1 · China · 1 site
Registry update: 1 Dec 2025
NCT06654596
Recruiting
Efficacy and Safety of Telitacicept in IgAN
Not applicable · China · 1 site
Registry update: 1 Jan 2025
NCT06676007
Recruiting
A Multi-center Open Label Prospective Study on Early Initiation of Targeted-release Formulation of Budesonide in Patients With Primary IgA Nephropathy
Not applicable · China · 1 site
Registry update: 15 Jan 2026
NCT06466135
Recruiting
Study of WAL0921 in Patients With Glomerular Kidney Diseases
Phase 2 · Australia, United Kingdom, India, South Korea, Sri Lanka, Malaysia, United States · 50 sites
Registry update: 3 Aug 2026
NCT05510323
Recruiting
Efficacy of Immunosuppressive Therapy for IgA Nephropathy With Stage 3 or 4 CKD
Phase 3 · China · 1 site
Registry update: 6 May 2024
NCT05791162
Recruiting
Interest of Follicular Helper Lymphocytes / Regulatory Follicular Helper Lymphocytes Ratio in IgA Nephropathy
Not applicable · France · 1 site
Registry update: 21 Nov 2024
NCT05775042
Recruiting
Clinical Study of CM338 in the Treatment of Immunoglobulin A Nephropathy
Phase 2 · China · 1 site
Registry update: 15 Oct 2024
NCT04662723
Recruiting
Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.
Phase 4 · Italy · 50 sites
Registry update: 2 Apr 2025
NCT05234463
Recruiting
Study of the Link Between Complement Activation and IgA Nephropathy Severity
Not applicable · France · 1 site
Registry update: 19 Aug 2026
NCT05036850
Recruiting
China Kidney Patient Trials Network
Not applicable · China · 1 site
Registry update: 6 Mar 2023
NCT04557462
Recruiting
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
Phase 3 · Argentina, Australia, Belgium, Brazil, Canada, Chile, China, Colombia, Czechia, Germany, Denmark, Spain, France, United Kingdom, Hong Kong, Hungary, Israel, India, Italy, Japan, South Korea, Mexico, Malaysia, Netherlands, Norway, Russia, Sweden, Singapore, Slovenia, Slovakia, Thailand, Taiwan, United States, Vietnam, South Africa · 134 sites
Registry update: 5 Oct 2026
Conflicting statuses (not updated in the registry for 1 month)
NCT05003986
Recruiting
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
Phase 2 · Germany, Spain, United Kingdom, Italy, Netherlands, Poland, Sweden, United States · 45 sites
Registry update: 12 May 2026
NCT06760845
Recruiting
Raman Spectroscopy Diagnosis of Kidney Diseases
Not applicable · China · 1 site
Registry update: 7 Jan 2025
NCT04663204
Recruiting
A Study of the Safety and Activity of Sparsentan for the Treatment of Patients With Immunoglobulin A Nephropathy
Phase 2 · United Kingdom · 6 sites
Registry update: 3 Jun 2026

Ordered by registry start date. Freshness and sponsorship never change the order.